Jennifer K. Simpson
CIK 1545253 · President and CEO · last filed 2024-10-03
Jennifer K. Simpson is a President and CEO who has filed 29 SEC Form 4 insider transactions across 4 companies since 2012. Across all open-market trades the lifetime net is +$20.4K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $293.3K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$293.3K
4
29
$20.4K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PBLA | President and CEO | 7,868 | $0.01 | $87 | $0 | 4 | 2023-03-29 |
| EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Director | — | $2.14 | — | $0 | 5 | 2023-03-09 |
| Panbela Therapeutics, Inc. (SNBP) Delisted | President and CEO | 3,424 | — | — | $2.7K | 2 | 2020-09-14 |
| DCTH | President and CEO | 25,021 | $11.72 | $293.2K | $17.7K | 13 | 2020-05-08 |
Recent Filings
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-10-03 | — | Grant (A) | — | $0 | |
| 2024-01-29 | — | Grant (A) | — | $0 | |
| 2023-03-29 | PBLA | Grant (A) | — | $0 | EDGAR |
| 2023-03-09 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-02-01 | PBLA | Buy (P) | +4,444 | $0 | EDGAR |
| 2022-03-02 | EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-11 | — | Grant (A) | — | $0 | |
| 2021-12-17 | — | Grant (A) | +25,000 | $0 | |
| 2021-09-15 | PBLA | Grant (A) | — | $0 | EDGAR |
| 2021-04-01 | PBLA | Grant (A) | — | $0 | EDGAR |